Prognostic value of early response to treatment combined with conventional risk factors in pediatric acute lymphoblastic leukemia

International Journal of Hematology

Volumn 81, Issue 3, 2005, Pages 228-234

  Morimoto, Akira ^a   Kuriyama, Kikuko ^a   Hibi, Shigeyoshi ^a   Todo, Shinjiro ^a   Yoshihara, Takao ^b   Kuroda, Hiroshi ^c   Imashuku, Shinsaku ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c KYOTO CITY HOSPITAL   (Japan)

Author keywords

Acute lymphoblastic leukemia; Bone marrow response; Mortality; Prognosis; Risk factor

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK FACTOR; ACUTE LYMPHOCYTIC LEUKEMIA; DISEASE FREE SURVIVAL; FOLLOW UP; INFANT; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 20344383722     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04114     Document Type: Article

References (16)

1. Donadieu J, Auclerc MF, Baruchel A, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables: Fralle group. French Acute Lymphoblastic Leukaemia study group. Br J Haematol. 1998;102:729-739.
2. Mastrangelo R, Poplack D, Bleyer A, Riccardi R, Sather H, D'Angio G. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol. 1986;14:191-194.
3. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989;7:1807-1815.
4. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80:1717-1726.
5. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
6. Donadieu J, Hill C. Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review. Br J Haematol. 2001;115:34-45.
7. Takanashi M, Morimoto A, Yagi T, et al. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica. 2003;88:1238-1244.
8. Schrappe M, Reiter A, Zimmerman M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1993. Leukemia. 2000;14:2205-2222.
9. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: report from the Children's Cancer Group. J Clin Oncol. 1996;14:389-398.
10. Goulden N, Oakhill A, Steward C. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;112:275-281.
11. Lilleyman JS. Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia. Leuk Lymphoma. 1998;31:501-506.
12. Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100:2399-2402.
13. Brisco MJ, Sykes PJ, Hughes E, et al. Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia. Leukemia. 2001;15:385-390.
14. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
15. Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 2002;100:420-426.
16. Uderzo C, Balduzzi A. Allogeneic bone marrow transplantation versus chemotherapy in childhood very high risk acute lymphoblastic leukemia in first complete remission: a controversial issue. Haematologica. 2002;87(suppl):47-50.